Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
Accesswire
· *Announces next-generation COVID-19 vaccine candidate as fourth respiratory vaccine to successfully meet its Phase 3..
· *Announces next-generation COVID-19 vaccine candidate as fourth respiratory vaccine to successfully meet its Phase 3..
New research shows that the recently emerged BA.2.86 omicron subvariant of the virus that causes COVID-19 can be neutralized by..
*CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business..
Issuer: CureVac / Key word(s): Study results
01.11.2023 / 13:00 CET/CEST
The issuer is solely responsible for the content..